Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The Transpacific TAVR Registry is a clinical study that looks at how well a procedure called Transcatheter Aortic Valve Replacement (TAVR) works for patients with heart valve diseases, particularly those with a condition known as aortic valve insufficiency. This procedure is a less invasive way to replace a damaged heart valve, and the study aims to gather information on how patients do over a long period after having TAVR in real-life settings.
To participate in this study, patients must be undergoing the TAVR procedure and provide their informed consent, meaning they understand what the study involves and agree to take part. The trial is currently open for recruiting participants of any age (starting from 69 years old) and gender. If you or a loved one are considering TAVR, this registry can provide valuable insights into the long-term effects of the procedure, and participants will help contribute to a better understanding of its outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients undergoing TAVR
- • Informed consent
About Duk Woo Park, Md
Dr. Duk-Woo Park, MD, is a distinguished clinical trial sponsor renowned for his commitment to advancing medical research and improving patient outcomes. With extensive experience in clinical medicine and trial management, Dr. Park leads innovative studies that explore cutting-edge therapies and treatment modalities. His collaborative approach fosters partnerships with leading institutions and research organizations, ensuring rigorous adherence to ethical standards and regulatory compliance. Driven by a passion for enhancing healthcare, Dr. Park is dedicated to translating scientific discoveries into practical applications that benefit patients and the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Chicago, Illinois, United States
Seoul, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Hangzhou, , China
Bucheon, , Korea, Republic Of
Patients applied
Trial Officials
Alan Ching Yuen Yeung, MD
Principal Investigator
Stanford University
James D. Flaherty, MD
Principal Investigator
Northwestern University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials